Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

MUC1 (Mucin 1)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

FusionPlex™ Pan-Heme panel

FusionPlex™ Pan-Heme panel

›

TA-MUC1 positive	Ovarian Cancer	TA-MUC1 positive	Ovarian Cancer	gatipotuzumab Sensitive: C2 – Inclusion Criteria gatipotuzumab Sensitive : C2	gatipotuzumab Sensitive: C2 – Inclusion Criteria gatipotuzumab Sensitive : C2
KRT7 expression + MUC1 expression	Ampulla of Vater Carcinoma	KRT7 expression + MUC1 expression	Ampulla of Vater Carcinoma	gemcitabine + albumin-bound paclitaxel Sensitive: C3 – Early Trials gemcitabine + albumin-bound paclitaxel Sensitive : C3	gemcitabine + albumin-bound paclitaxel Sensitive: C3 – Early Trials gemcitabine + albumin-bound paclitaxel Sensitive : C3
MUC1 elevation	HER2 Positive Breast Cancer	MUC1 elevation	HER2 Positive Breast Cancer	ado-trastuzumab emtansine Sensitive: C3 – Early Trials ado-trastuzumab emtansine Sensitive : C3	ado-trastuzumab emtansine Sensitive: C3 – Early Trials ado-trastuzumab emtansine Sensitive : C3
MUC1 underexpression	Pancreatic Ductal Adenocarcinoma	MUC1 underexpression	Pancreatic Ductal Adenocarcinoma	gemcitabine Sensitive: C3 – Early Trials gemcitabine Sensitive : C3	gemcitabine Sensitive: C3 – Early Trials gemcitabine Sensitive : C3
TA-MUC1 elevation + EGFR expression	Colorectal Cancer	TA-MUC1 elevation + EGFR expression	Colorectal Cancer	gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials gatipotuzumab + tomuzotuximab Sensitive : C3	gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials gatipotuzumab + tomuzotuximab Sensitive : C3
TA-MUC1 elevation + EGFR expression	Breast Cancer	TA-MUC1 elevation + EGFR expression	Breast Cancer	gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials gatipotuzumab + tomuzotuximab Sensitive : C3	gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials gatipotuzumab + tomuzotuximab Sensitive : C3
TA-MUC1 elevation + EGFR expression	Head and Neck Cancer	TA-MUC1 elevation + EGFR expression	Head and Neck Cancer	gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials gatipotuzumab + tomuzotuximab Sensitive : C3	gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials gatipotuzumab + tomuzotuximab Sensitive : C3
TA-MUC1 elevation + EGFR expression	Non Small Cell Lung Cancer	TA-MUC1 elevation + EGFR expression	Non Small Cell Lung Cancer	gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials gatipotuzumab + tomuzotuximab Sensitive : C3	gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials gatipotuzumab + tomuzotuximab Sensitive : C3
MUC1 elevation	Non Small Cell Lung Cancer	MUC1 elevation	Non Small Cell Lung Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
MUC1 expression	Ovarian Cancer	MUC1 expression	Ovarian Cancer	P-MUC1C-ALLO1 Sensitive: D – Preclinical P-MUC1C-ALLO1 Sensitive : D	P-MUC1C-ALLO1 Sensitive: D – Preclinical P-MUC1C-ALLO1 Sensitive : D
MUC1 overexpression	Pancreatic Ductal Adenocarcinoma	MUC1 overexpression	Pancreatic Ductal Adenocarcinoma	BBI608 Sensitive: D – Preclinical BBI608 Sensitive : D	BBI608 Sensitive: D – Preclinical BBI608 Sensitive : D
MUC1 expression	HER2 Positive Breast Cancer	MUC1 expression	HER2 Positive Breast Cancer	MUC1 inhibitor Sensitive: D – Preclinical MUC1 inhibitor Sensitive : D	MUC1 inhibitor Sensitive: D – Preclinical MUC1 inhibitor Sensitive : D